Colby gets exclusive rights to MannKind's cancer immunotherapy program
Colby Pharmaceutical Co. (signal transduction modulators and immune modulators for various diseases) has licensed exclusive worldwide rights to develop and sell diabetes and cancer firm MannKind Corp.’s disease-specific antigen compounds and associated intra-lymph node injection (ILNI) delivery technologies from the company’s MKC1106 immunotherapy program, including lead candidate MKC1106MT.
- Site Specific
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.